Precision and Future Medicine10.23838/pfm.2018.000162018218-17Telomerase reverse transcriptase promoter mutation and its clinical implication in thyroid cancerJae Hoon Chung,,
Thyroid10.1089/thy.2018.0314201929111623-1633ETS Factor ETV5 Activates the Mutant Telomerase Reverse Transcriptase Promoter in Thyroid CancerMartyn Bullock, Grace Lim, Ying Zhu, Helena Ã…berg, Sergey Kurdyukov, Roderick Clifton-Bligh,
Genes10.3390/genes707003820167738Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical ImplicationsTiantian Liu, Xiaotian Yuan, Dawei Xu
Clinical Radiology10.1016/j.crad.2022.04.0052022778e560-e567A radiomics feature-based nomogram to predict telomerase reverse transcriptase promoter mutation status and the prognosis of lower-grade gliomasJ. Lu, X. Li, H. Li,
Thyroid10.1089/thy.2020.0055202030101470-1481Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell LinesBrittany A. McKelvey, Timothy Gilpatrick, Yongchun Wang, Winston Timp, Christopher B. Umbricht, Martha A. Zeiger,
Molecular Therapy10.1016/s1525-0016(16)44009-8200255S3831179. Cancer-Specific Killing by the Suicide Gene (CD) Using the Human Telomerase Reverse Transcriptase Promoter,
Science-Business eXchange10.1038/scibx.2013.3252013613325-325Highly prevalent telomerase reverse transcriptase ( TERT ) promoter mutations in tumors including glioblastoma and bladder cancer,,
OncoTargets and Therapy10.2147/ott.s1165942016Volume 96965-6976Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysisXingyun Su, Xiaoxia Jiang, Weibin Wang, Haiyong Wang, Xin Xu, Aihui Lin, Xiaodong Teng, Huiling Wu, Lisong Teng,
Clinical Thyroidology10.1089/ct.2017;29.176-1792017295176-179Meta-Analysis Confirms the Deleterious Effects of CombinedBRAFV600Eand Telomerase Reverse Transcriptase Promoter Mutations on the Course and Mortality of Papillary Thyroid CarcinomaCharles H. Emerson,
Molecular Therapy10.1016/j.ymthe.2004.06.54420049S235620. A Longer Human Telomerase Reverse Transcriptase Promoter-Based Conditionally Replicative Adenovirus Shows Oncolysis with Less Toxicity for Ovarian Cancer Treatment,